Webcast to Review CUSTOM III Six-Month Data to be held Tuesday, May 13th
MENLO PARK, Calif., May 7 /PRNewswire-FirstCall/ -- XTENT, Inc.
(Nasdaq: XTNT) today announced that six-month follow-up data from the
CUSTOM III trial will be presented at EuroPCR, taking place May 13 to 16 in
Barcelona. The company will hold a webcast and conference call to review
the new CUSTOM III data immediately following the late-breaking session. In
addition, two-year CUSTOM I data, previously presented at the Transcatheter
Cardiovascular Therapeutics (TCT) meeting last October, has been accepted
for publication in the May issue of EuroIntervention. Professor Grube, the
CUSTOM I principal investigator, has been asked to present the data during
a EuroPCR session on the six best papers from EuroIntervention. XTENT is
also sponsoring an evening symposium on customizable drug-eluting stents
and will exhibit throughout the meeting at booth E11 in the main hall.
Schedule of XTENT Events for EuroPCR
Tuesday, May 13, 2008, 3:30-6:30 p.m. CEST, Room 1
Late-Breaking Clinical Trial: CUSTOM III trial 6-month follow-up results.
Bernard de Bruyne, M.D., Ph.D, Cardiovascular Center, OLV Hospital in Aalst, Belgium, the principal investigator of the CUSTOM III clinical trial, will present six-month follow-up data from the CUSTOM III trial evaluating use of the Custom NX(R) Drug Eluting Stent (DES) System in patients with long or multiple coronary lesions.
Tuesday, May 13, 2008, 7:00 p.m. CEST (1:00 p.m. EDT)
CUSTOM III webcast and conference call.
To participate in the conference call, please dial 877-591-4957 (from the U.S.) or 719-325-4895 (international). The webcast and slide presentation can be accessed via the investor relations section of the Company's website at http://investor.xtentinc.com/events.cfm. Please dial in or access the website five to 10 minutes prior to the beginning of the call. If you do dial-in, please also view the slides via the webcast. The webcast will be archived on the website for a minimum of three months, and can be accessed at the investor relations portion of the company's website at http://investor.xtentinc.com
Wednesday, May 14, 2008, 5:00-6:30 p.m. CEST, Room 5
Evening symposium: Customizable drug-eluting stents: a breakthrough approach to the percutaneous treatment of coronary artery disease.
The symposium will provide an overview of the Custom NX DES System with respect to the treatment of long and multi-lesion coronary artery disease, and the CUSTOM clinical program.
Thursday, May 15 12:00-1:30 pm CEST, Room 122/123
EuroIntervention @ EuroPCR: CUSTOM I two-year follow-up results
Eberhard Grube, M.D., Chief of Cardiology at the HELIOS Heart Center in Siegburg, Germany, the principal investigator of the CUSTOM I clinical trial, will present two year follow-up data from the CUSTOM I trial.
About the Custom NX(R) DES System
Custom NX is designed to enable a more personalized approach to the treatment of arterial disease based on each patient's individual lesion characteristics. The Custom NX system allows physicians to customize the length and diameter of the stent at the site of the lesion. The system features a proprietary modular stent design that consists of multiple 6mm cobalt chromium segments coated with Biolimus A9(R) and PLA, a biodegradable drug carrier. The Custom NX delivery system enables separation at each 6mm segment and allows for the placement of up to 60mm of stent.
XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the timing of the release of its clinical trial data. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's annual report on Form 10-K for the year ended December 31, 2007. This annual report was filed with the SEC on March 17, 2008, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
|SOURCE XTENT, Inc.|
Copyright©2008 PR Newswire.
All rights reserved